SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.
For other questions, please call Member Services at the number on the back of your member ID card.
A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).
Sarepta Suspends ELEVIDYS for Non-Ambulatory Clients
Date: June 20, 2025
Attention: Providers
URGENT PATIENT SAFETY NOTICE: Sarepta suspends the drug, ELEVIDYS (HCPCS code J1413) for Non-ambulatory patients with Duchene muscular dystrophy due to patient safety concerns including risk for acute liver failure and death.
Providers should halt the administration of ELEVIDYS for non-ambulatory clients while an enhanced immunosuppressive regimen is evaluated.
Additional information: ELEVIDYS (Delandistrogene moxeparvovec-rokl) is an adeno-associated virus vector-based gene therapy indicated for the treatment of ambulatory and non-ambulatory individuals who are four years or older with Duchenne muscular dystrophy (DMD) and have a confirmed mutation in the DMD gene. Sarepta is suspending shipments of ELEVIDYS for non-ambulatory clients.
Next step for Providers: Non-ambulatory members initially approved for Elevidys should stop taking the drug until more information is known about how to prevent this. Texas Children’s Health Plan will publish more information as it becomes available at www.texaschildrenshealthplan.org/provideralerts. Additionally, providers can reference Texas Medicaid and Healthcare Partnership for updates under Recent News.
